{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:00:47Z","timestamp":1792404047301,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jpba.2025.116683","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:31:49Z","timestamp":1737545509000},"page":"116683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Simultaneous determination of busulfan, fludarabine, phenytoin, and posaconazole in plasma from patients undergoing hematopoietic stem cell transplantation"],"prefix":"10.1016","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9666-7250","authenticated-orcid":false,"given":"Xijuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yile","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2025.116683_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/157488407779422249","article-title":"Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring","volume":"2","author":"Nath","year":"2007","journal-title":"Curr. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2025.116683_bib2","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.drudis.2014.04.005","article-title":"Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics","volume":"19","author":"ten Brink","year":"2014","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.jpba.2025.116683_bib3","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.bbmt.2007.08.002","article-title":"Spanish Myeloma Group\/PETHEMA, Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients","volume":"13","author":"Carreras","year":"2007","journal-title":"Biol. Blood. Marrow Transplant."},{"key":"10.1016\/j.jpba.2025.116683_bib4","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.jpba.2025.116683_bib5","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","article-title":"Personalizing busulfan-based conditioning: considerations from the American society for blood and marrow transplantation practice guidelines committee","volume":"22","author":"Palmer","year":"2016","journal-title":"Biol. Blood. Marrow Transplant."},{"key":"10.1016\/j.jpba.2025.116683_bib6","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood-2002-11-3567","article-title":"Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells","volume":"102","author":"Bornhauser","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2025.116683_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchromb.2013.05.012","article-title":"Improved quantitative method for fludarabine in human plasma by liquid chromatography and tandem mass spectrometry","volume":"931","author":"Ng","year":"2013","journal-title":"J. Chromatogr. B. Anal. Technol. Biomed. Life. Sci."},{"key":"10.1016\/j.jpba.2025.116683_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00280-014-2618-2","article-title":"Population pharmacokinetic\/dynamic model of lymphosuppression after fludarabine administration","volume":"75","author":"McCune","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2025.116683_bib9","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1158\/1078-0432.CCR-09-0427","article-title":"A limited sampling schedule to estimate individual pharmacokinetic parameters of fludarabine in hematopoietic cell transplant patients","volume":"15","author":"Salinger","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2025.116683_bib10","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1592\/phco.28.12.1502","article-title":"Optimal prevention of seizures induced by high-dose busulfan","volume":"28","author":"Eberly","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpba.2025.116683_bib11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2025.116683_bib12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2025.116683_bib13","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/17425255.2019.1671971","article-title":"Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients","volume":"15","author":"John","year":"2019","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"10.1016\/j.jpba.2025.116683_bib14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/jcph.130","article-title":"Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation","volume":"53","author":"de Castro","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2025.116683_bib15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/jcph.1027","article-title":"Population pharmacokinetics of intravenous busulfan in Japanese pediatric patients with primary immunodeficiency diseases","volume":"58","author":"Ishiwata","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2025.116683_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00686213","article-title":"Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics","volume":"33","author":"Hassan","year":"1993","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2025.116683_bib17","first-page":"3025","article-title":"Dose-adjusted concentrations of posaconazole oral suspension in hematopoietic stem cell transplantation patients and analysis of the influential factors","volume":"34","author":"Dong","year":"2023","journal-title":"China Pharm."},{"key":"10.1016\/j.jpba.2025.116683_bib18","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.3390\/molecules25174026","article-title":"Review of chromatographic methods coupled with modern detection techniques applied in the therapeutic drugs monitoring (TDM)","volume":"25","author":"Tuzimski","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jpba.2025.116683_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jchromb.2017.04.025","article-title":"Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS\/MS for exposure monitoring in hematopoietic cell transplantation conditioning","volume":"1055\u20131056","author":"Punt","year":"2017","journal-title":"J. Chromatogr. B. Anal. Technol. Biomed. Life. Sci."},{"key":"10.1016\/j.jpba.2025.116683_bib20","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1556\/1326.2022.01069","article-title":"Simultaneously measure the concentrations of busulfan and phenytoin in human plasma using an HPLC-MS\/MS method: application to the TDM for children underwent hematological stem cell transplantation","volume":"35","author":"Sun","year":"2023","journal-title":"Acta Chromatogr."},{"key":"10.1016\/j.jpba.2025.116683_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4898","article-title":"A rapid HPLC-MS\/MS method for determining busulfan in hemolytic samples from children with hematopoietic stem cell transplantation","volume":"34","author":"Jinjie","year":"2020","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2025.116683_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cca.2017.08.032","article-title":"Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantitation of 5 azole antifungals and 1 active metabolite","volume":"474","author":"McShane","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jpba.2025.116683_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5484","article-title":"An LC-ESI-MS\/MS assay for the therapeutic drug monitoring of 15 antiseizure medications in plasma of children with epilepsy","volume":"36","author":"Zhang","year":"2022","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2025.116683_bib24","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1038\/s41598-020-65919-9","article-title":"UPLC-tandem mass spectrometry for quantification of busulfan in human plasma: application to therapeutic drug monitoring","volume":"10","author":"Matar","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jpba.2025.116683_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114216","article-title":"Fast and reliable quantification of busulfan in blood plasma using two-channel liquid chromatography tandem mass spectrometry: Validation of assay performance in the presence of drug formulation excipients","volume":"203","author":"Andersen","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.116683_bib26","unstructured":"EMA, Committee for medicinal products for human use, in: Guideline on Bioanalytical Method Validation, EMEA\/CHMP\/EWP\/192217\/2009 Rev. 1 Corr.2*\u2009*, 2012, pp. 1-23."},{"key":"10.1016\/j.jpba.2025.116683_bib27","series-title":"Handbook of LC-MS Bioanalysis: Best Practices, Experimental Protocols, and Regulations","author":"Li","year":"2017"},{"key":"10.1016\/j.jpba.2025.116683_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114562","article-title":"Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma\/serum using UPLC-MS\/MS for therapeutic drug monitoring","volume":"211","author":"Zhang","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2025.116683_bib29","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.jasms.2004.04.034","article-title":"Charge competition and the linear dynamic range of detection in electrospray ionization mass spectrometry","volume":"15","author":"Tang","year":"2004","journal-title":"J. Am. Soc. Mass. Spectrom."},{"key":"10.1016\/j.jpba.2025.116683_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/rcm.6777","article-title":"A high dynamic range pulse counting detection system for mass spectrometry","volume":"28","author":"Collings","year":"2014","journal-title":"Rapid. Commun. Mass. Spectrom."},{"key":"10.1016\/j.jpba.2025.116683_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.15583\/jpchrom.2017.004","article-title":"Expanding the versatility of a quantitative determination range adjustment technique using in-source CID in LC\/MS\/MS","volume":"38","author":"Ishii","year":"2017","journal-title":"Chromatography"},{"key":"10.1016\/j.jpba.2025.116683_bib32","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1515\/CCLM.2004.245","article-title":"Therapeutic drug monitoring of old and newer anti-epileptic drugs","volume":"42","author":"Neels","year":"2004","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.jpba.2025.116683_bib33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole","volume":"80","author":"Chen","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2025.116683_bib34","first-page":"935","article-title":"Pharmacokinetics of intravenous busulfan in patients prior to allogeneic hematopoietic stem cell transplantation","volume":"45","author":"Zhang","year":"2010","journal-title":"Chin. Pharm. J."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852500024X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852500024X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:13:21Z","timestamp":1762308801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170852500024X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":34,"alternative-id":["S073170852500024X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116683","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous determination of busulfan, fludarabine, phenytoin, and posaconazole in plasma from patients undergoing hematopoietic stem cell transplantation","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116683"}}